Use of Catestatin to Mobilize Fat from Adipose Tissue by Regulating Adrenergic and Leptin Signaling
- Detailed Technology Description
- Scientists at the University of California, San Diego have discovered that catestatin reduces adipose tissue weight by stimulating breakdown of fat (lipolysis) and disposing of the released fatty acids by oxidation in both liver and adipose tissue. This technology supports an essential role of the endogenous bioactive peptide catestatin in restoring homeostasis during metabolic disorders by controlling catecholamine release and lipid disposal via modulation of adrenergic and leptin signaling. Therefore, CST may be developed as an anti-obesity agent.
- Supplementary Information
- Inventor: MAHATA, Sushil, K. | BANDYOPADHYAY, Gautam, K.
Priority Number: WO2013149259A1
IPC Current: A61K003817 | A61P000300 | A61P000304 | C07K001447 | C07K001618
Assignee Applicant: The Regents of the University of California
Title: METHOD FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN | PROCÉDÉ POUR STIMULER LA LIPOLYSE ET L'OXYDATION DANS LE FOIE ET LE TISSU ADIPEUX AVEC DE LA CATÉSTATINE
Usefulness: METHOD FOR PROMOTING LIPOLYSIS AND OXIDATION IN LIVER AND ADIPOSE TISSUE USING CATESTATIN | PROCÉDÉ POUR STIMULER LA LIPOLYSE ET L'OXYDATION DANS LE FOIE ET LE TISSU ADIPEUX AVEC DE LA CATÉSTATINE
Summary: For treating obesity in a subject, where the subject is diabetic, overweight, diabetic, leptin deficient, leptin resistant, hyperleptineniic, pancreastatin deficient, chromogranin A deficient, insulin resistant, hyperinsulinemic or has low plasma levels of naturally occurring CST or can benefit from treating obesity, where the overweight subject is obese; to treat obesity which is associated with diet induced obesity or associated with a condition or disorder associated with reduced chromogranin A expression, reduced circulating CST, decreased sensitivity of β -adrenergic receptor, increased circulating catecholamines or increased circulating leptin; to restore leptin sensitivity or insulin sensitivity to a subject; to promote lipolysis and/or fatty acid oxidation, where lipolysis or fatty acid oxidation occurs in the adipose tissue or liver; to promote lipid transfer for catabolism in the liver from adipocytes; for reversing leptin resistance in the brain or peripheral tissue of a subject; for decreasing triglyceride levels in the plasma of a subject; for increasing the therapeutic effectiveness of an anti-diabetic drug, by reducing undesirable side effects associated with the anti-diabetic drug in a subject; for enhancing lipolysis in a subject; for increasing fatty acid oxidation and/or lipid flux from adipose tissue toward liver for catabolism in a subject; for increasing lipolysis in adipose tissue and fatty acid uptake and oxidation in liver of a subject; for reducing circulating insulin levels in an insulin resistant subject thus minimizing chronic exposure to persistently high levels of insulin which may cause desensitization of insulin action; for stimulating expression of a transporter which mediates the cellular uptake of long-chain fatty acids in a subject; for reducing food intake in a leptin-deficient subject; for restoring or increasing insulin sensitivity in a diabetic or insulin resistant subject (all claimed).
Novelty: Treating obesity in a subject involves administering catestatin to subject so as to maintain circulating catestatin in subject to promote lipolysis and oxidation of released fatty acids in both liver and adipose tissue
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- 9572862
- Others
-
Related Materials
Tech ID/UC Case
22551/2012-314-0
Related Cases
2012-314-0
- *Abstract
-
Chromogranin A (CHGA/Chga), a 48-kDa acidic secretory proprotein, gives rise to several peptides of biological importance, which include the dysglycemic hormone pancreastatin, the vasodilator vasostatin, and the antihypertensive peptide catestatin that inhibits catecholamine release. Initially identified as a physiological brake in catecholamine secretion, catestatin has been established as a pleiotropic hormone having effects on promoting angiogenesis and lowering blood pressure.
- *IP Issue Date
- Feb 21, 2017
- *Principal Investigator
-
Name: Gautam Bandyopadhyay
Department:
Name: Sushil Mahata
Department:
Name: Sushil Mahata
Department:
- Country/Region
- USA
For more information, please click Here
